A2 Biotherapeutics, Inc.

📍 Agoura Hills, United States🗓 Founded 2018👥 131 employees💰 Last funded Jan 2018
Biotechnology Research🌐 a2bio.com
Website LinkedIn
A2 is dedicated to pushing the boundaries of science to transform medicine and turn the tide on cancer. We are focused on the next frontier in cell therapy: solid tumors. A2 engineers T cells that target the loss of genetic material in tumors, enabling the selective killing of tumor cells while leaving normal cells unharmed. The company was founded in 2018 by Alexander Kamb, Michael Gallo and Paul Kang and has raised $136M since inception. Our investors include The Column Group, Vida Ventures, Samsara BioCapital, Nextech Invest, Casdin Capital, Euclidean Capital, UC Investments (Office of the Chief Investment Officer of the Regents) and Hartford HealthCare Endowment.
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2018
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Switzerland
1
Frequently asked questions
Who invested in A2 Biotherapeutics, Inc.?
A2 Biotherapeutics, Inc. has 1 investors on record on gritt.io, including 1 early-stage backers.
When did A2 Biotherapeutics, Inc. last raise funding?
The most recent investment in A2 Biotherapeutics, Inc. recorded on gritt.io was in January 2018.
When was A2 Biotherapeutics, Inc. founded?
A2 Biotherapeutics, Inc. was founded in 2018.
What industry is A2 Biotherapeutics, Inc. in?
A2 Biotherapeutics, Inc. operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is A2 Biotherapeutics, Inc. based?
A2 Biotherapeutics, Inc. is headquartered in Agoura Hills, United States.